Megesin

Megestrol acetate, the active ingredient in Megesin, is a progestogen presented as an oral formulation for oral use. It is employed to stimulate appetite and manage hormone‑responsive malignancies, particularly in patients with cancer‑related cachexia or AIDS‑associated weight loss. It is indicated for individuals experiencing severe weight loss due to chronic illness and for certain hormone‑sensitive tumors.

GNH USA supplies Megesin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory‑approved batches to meet global demand.

Megesin (megestrol acetate) acts as a progestogenic agent that influences metabolic and hormonal pathways associated with weight loss and hormone‑sensitive cancers. - Cachexia associated with AIDS or cancer: improves appetite and promotes weight gain in affected patients. - Anorexia and weight loss: increases food intake and helps restore body mass. - Hormone‑responsive cancers such as endometrial or breast cancer: provides antigonadotropic effects that can slow tumor progression.

Megestrol acetate may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Weight gain: excess increase in body weight. - Increased appetite: heightened desire for food. - Nausea: occasional stomach upset. - Edema: mild fluid retention, especially in the lower limbs. Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Hyperglycemia: significant rise in blood glucose levels. - Adrenal insufficiency: reduced cortisol production. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

When prescribing Megesin, clinicians should consider several safety measures to minimize risks. - Monitor blood glucose: check fasting and post‑prandial levels regularly. - Assess thromboembolic risk: evaluate history of clotting disorders before initiation. - Observe blood pressure: watch for hypertension, especially in patients with cardiovascular disease. - Evaluate adrenal function: consider cortisol testing if long‑term therapy is planned. - Use caution in pregnancy: potential fetal effects are not well established; avoid unless benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Megestrol acetate can alter the activity of several concomitant medicines, requiring attention to interaction potential. Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, phenytoin): may markedly reduce megestrol exposure. - Anticoagulants (warfarin): increased risk of thrombosis may counteract anticoagulant effect. - Antifungal agents (ketoconazole, itraconazole): can raise megestrol levels and increase toxicity. Moderate Interactions (Monitor Closely): - Corticosteroids: additive fluid retention and metabolic effects. - Insulin or oral hypoglycemics: may exacerbate hyperglycemia, requiring closer monitoring. - Other hormonal therapies (tamoxifen, aromatase inhibitors): could interfere with endocrine balance.